Stevanato Group Spa (NYSE:STVN) Expected to Announce Quarterly Sales of $239.04 Million

Brokerages expect Stevanato Group Spa (NYSE:STVN) to announce sales of $239.04 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Stevanato Group’s earnings. The highest sales estimate is $240.72 million and the lowest is $236.99 million. The firm is expected to issue its next earnings report on Thursday, November 18th.

On average, analysts expect that Stevanato Group will report full-year sales of $968.77 million for the current financial year, with estimates ranging from $965.47 million to $972.72 million. For the next year, analysts forecast that the company will report sales of $1.06 billion, with estimates ranging from $1.05 billion to $1.06 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Stevanato Group.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, August 19th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. The company had revenue of $245.77 million during the quarter, compared to the consensus estimate of $239.72 million.

Several equities analysts have recently commented on the company. Wells Fargo & Company began coverage on Stevanato Group in a research report on Tuesday, August 10th. They issued an “overweight” rating and a $24.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Stevanato Group from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, August 20th. UBS Group began coverage on shares of Stevanato Group in a research note on Tuesday, August 10th. They issued a “neutral” rating and a $22.00 price target on the stock. Bank of America assumed coverage on Stevanato Group in a report on Tuesday, August 10th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Citigroup assumed coverage on Stevanato Group in a research note on Tuesday, August 10th. They issued a “buy” rating and a $27.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $26.29.

NYSE STVN traded up $0.62 on Monday, reaching $28.40. 4,459 shares of the stock were exchanged, compared to its average volume of 853,188. Stevanato Group has a one year low of $16.61 and a one year high of $28.66. The firm’s 50-day moving average price is $23.54.

Stevanato Group Company Profile

Stevanato Group S.p.A. is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group S.p.A. is based in PIOMBINO DESE, Italy.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Stevanato Group (STVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stevanato Group (NYSE:STVN)

Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.